[go: up one dir, main page]

AR126161A1 - Moléculas de fijación triespecíficas novedosas - Google Patents

Moléculas de fijación triespecíficas novedosas

Info

Publication number
AR126161A1
AR126161A1 ARP220101585A ARP220101585A AR126161A1 AR 126161 A1 AR126161 A1 AR 126161A1 AR P220101585 A ARP220101585 A AR P220101585A AR P220101585 A ARP220101585 A AR P220101585A AR 126161 A1 AR126161 A1 AR 126161A1
Authority
AR
Argentina
Prior art keywords
molecules
binding molecules
binding
fixation
compositions
Prior art date
Application number
ARP220101585A
Other languages
English (en)
Inventor
Paul Adam
Stephen R Comeau
Philip Nicholas Gorman
Pankaj Gupta
Priyanka Gupta
Karl Heider
- Kasturirangan Srinath Heinz
Renate Konopitzky
Klaus Kuenkele
- Kumar Sandeep Peter
Taneisha Ann Mack
- Ostermann Elinborg Katrin Tanara
Abdulsalam Shaaban
David Weismann
Andreas Wernitznig
David S Young
Original Assignee
Boehringer Lngelheim Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Lngelheim Int Gmbh filed Critical Boehringer Lngelheim Int Gmbh
Publication of AR126161A1 publication Critical patent/AR126161A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Moléculas de fijación triespecíficas novedosas. También ácidos nucleicos que codifican tales moléculas de fijación; métodos para preparar tales moléculas de fijación; células huésped que expresan o son capaces de expresar tales moléculas de fijación; composiciones que comprenden tales moléculas de fijación; y usos de tales moléculas de fijación o tales composiciones, en particular con fines terapéuticos en el campo de las enfermedades cancerosas. Reivindicación 1: Una molécula de fijación caracterizada porque comprende: (a) al menos un sitio de fijación al antígeno que se fija específicamente al antígeno de la superficie de trofoblastos 2 (TROP2) con una Kd & Reivindicación 11: Una molécula de ácido nucleico caracterizada porque codifica la molécula de fijación de acuerdo con cualquiera de las reivindicaciones 1 a 10, o una parte de esta. Reivindicación 12: Un vector de expresión caracterizado porque comprende una o más moléculas de ácido nucleico de acuerdo con la reivindicación 11. Reivindicación 13: Una célula huésped caracterizada porque es transfectada con el vector de expresión de acuerdo con la reivindicación 12. Reivindicación 15: Una composición farmacéutica caracterizada porque comprende o consiste en una o más moléculas de fijación de acuerdo con cualquiera de las reivindicaciones 1 a 10 y opcionalmente un portador aceptable desde el punto de vista farmacéutico.
ARP220101585A 2021-06-17 2022-06-15 Moléculas de fijación triespecíficas novedosas AR126161A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21180033 2021-06-17

Publications (1)

Publication Number Publication Date
AR126161A1 true AR126161A1 (es) 2023-09-27

Family

ID=76829270

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101585A AR126161A1 (es) 2021-06-17 2022-06-15 Moléculas de fijación triespecíficas novedosas

Country Status (7)

Country Link
US (1) US12275798B2 (es)
EP (1) EP4355778A1 (es)
JP (1) JP2024523033A (es)
CN (1) CN117957256A (es)
AR (1) AR126161A1 (es)
TW (1) TW202317625A (es)
WO (1) WO2022263507A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202434644A (zh) * 2023-02-07 2024-09-01 大陸商上海齊魯製藥研究中心有限公司 三特異性抗原結合分子及其應用
WO2025226918A1 (en) * 2024-04-24 2025-10-30 La Jolla Institute For Immunology Herv-k envelope protein binders and compositions and methods of use thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731A (en) 1848-08-22 Elisha k
US168A (en) 1837-04-17 Improvement in fire-arms
US4766980A (en) 1985-09-16 1988-08-30 General Signal Corporation Rail car brake apparatus
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP1589107B1 (en) 1992-08-21 2009-12-23 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
DK0703925T3 (da) 1993-06-03 1999-12-06 Therapeutic Antibodies Inc Fremstilling af antistoffragmenter
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
AU7266898A (en) 1997-04-30 1998-11-24 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
IL156955A0 (en) 2001-01-17 2004-02-08 Genecraft Inc Binding domain-immunoglobulin fusion proteins
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
EP2258392A1 (en) 2002-11-08 2010-12-08 Ablynx N.V. Method of administering therapeutic polypeptides
US7919089B2 (en) 2003-05-31 2011-04-05 Micromet Ag Pharmaceutical composition comprising a bispecific antibody for EpCAM
CA2527726A1 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. De-immunized anti-cd3 antibody
CA2529819A1 (en) 2003-06-30 2004-09-23 Domantis Limited Pegylated single domain antibodies
SG10201606980VA (en) 2004-06-03 2016-10-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
US20080107601A1 (en) 2004-10-13 2008-05-08 Ablynx N.V. Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease
RU2451449C2 (ru) 2005-06-30 2012-05-27 Зингента Партисипейшнс Аг Способ снижения уровня загрязнения урожая микотоксинами
BRPI0618399B1 (pt) 2005-10-12 2023-10-03 Morphosys Ag Anticorpo específico anti-cd38 humano, composição de ácido nucleico, vetor de expressão, composição farmacêutica, uso do anticorpo e uso de uma composição farmacêutica
JP2009014505A (ja) 2007-07-04 2009-01-22 Olympus Corp 汚れ検出装置および分析装置
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
TW201100543A (en) * 2009-05-27 2011-01-01 Hoffmann La Roche Tri-or tetraspecific antibodies
CN105693861A (zh) 2009-12-29 2016-06-22 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
BR112013027224A8 (pt) 2011-04-22 2018-08-14 Emergent Product Dev Seattle Proteínas de ligação de antígeno de membrana específico de próstata e composições e métodos relacionados
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
HRP20240939T1 (hr) 2013-12-17 2024-10-25 Genentech, Inc. Anti-cd3 protutijela i metode uporabe
JP6230957B2 (ja) 2014-05-29 2017-11-15 株式会社日立国際電気 検査装置及び検査方法
US9212225B1 (en) 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
ES2979976T3 (es) 2014-08-04 2024-09-27 Hoffmann La Roche Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas
EP2982693A1 (en) 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
ES2889906T3 (es) 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Proteínas de unión triespecíficas y usos médicos
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
JP6974348B2 (ja) * 2016-01-09 2021-12-01 アーベル リミテッドArbele Limited がん処置のためのカドヘリン−１７特異的抗体及び細胞傷害性細胞
RS61510B1 (sr) 2016-05-18 2021-03-31 Boehringer Ingelheim Int Anti pd-1 i anti-lag3 antitela za lečenje kancera
CN116987189A (zh) 2016-05-20 2023-11-03 哈普恩治疗公司 单链可变片段cd3结合蛋白质
US10316088B2 (en) 2016-06-28 2019-06-11 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
SMT202200359T1 (it) 2016-09-23 2022-11-18 Regeneron Pharma Anticorpi anti-muc16 (mucina 16)
MX2019006043A (es) 2016-11-23 2019-09-26 Harpoon Therapeutics Inc Proteína de unión de antígeno prostático específico de membrana.
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
DE102017006651A1 (de) 2017-07-13 2019-01-17 Gleason-Pfauter Maschinenfabrik Gmbh Verfahren zum Erzeugen eines verzahnten Werkstücks
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
TWI817974B (zh) 2017-12-28 2023-10-11 日商中外製藥股份有限公司 細胞毒性誘導治療劑
CA3115020A1 (en) 2018-12-21 2020-06-25 Anne Freimoser-Grundschober Antibodies binding to cd3
US20230340119A1 (en) 2019-12-05 2023-10-26 Arbele Corp Composition of triax antibodies and method of making and using thereof

Also Published As

Publication number Publication date
US20220411533A1 (en) 2022-12-29
JP2024523033A (ja) 2024-06-25
US12275798B2 (en) 2025-04-15
EP4355778A1 (en) 2024-04-24
WO2022263507A1 (en) 2022-12-22
TW202317625A (zh) 2023-05-01
CN117957256A (zh) 2024-04-30

Similar Documents

Publication Publication Date Title
AR126161A1 (es) Moléculas de fijación triespecíficas novedosas
TWI681966B (zh) Ｆｇｆ２１衍生物及其用途
Wang et al. Cancer vaccines using supramolecular hydrogels of NSAID-modified peptides as adjuvants abolish tumorigenesis
MX2021007449A (es) Molécula de unión dirigida a célula mejorada.
BR112022008744A2 (pt) Ligante de il-2rss, ligante de il-2r¿c, composto de ligação a il-2r¿¿c, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método de uma terapia celular, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico
CO2022003552A2 (es) Proteínas de fijación multiespecíficas para tratamiento contra el cáncer
BRPI0412125A (pt) molécula de ácido nucleico isolada, polipeptìdeo de fusão, vetor de expressão, método de produzir um polipeptìdeo de fusão de vegf, captador de fator de crescimento de célula endotelial vascular, composição farmacêutica, método de tratar uma doença ou condição que são restabelecidas, melhoradas ou inibidas pela remoção ou inibição do fator de crescimento endotelial vascular, e, artigo de fabricação
BR112022008750A2 (pt) Composto de ligação de receptor duplo, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico
ES2929303T3 (es) Composición de polideoxirribonucleótidos y usos de los mismos
BRPI0508424A (pt) muteìnas de interleucina-2 melhoradas
BR112017027985A2 (pt) peptídeos terapêuticos e métodos de uso dos mesmos
AR127629A1 (es) Moléculas de anticuerpo y conjugados
SG158870A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
BR112023019138A2 (pt) Proteína multiespecífica, composição farmacêutica, célula recombinante, método de preparação de uma composição de célula nk, composição de células nk, uso de uma proteína ou composição, métodos e uso
BR112022015002A2 (pt) Ligante de il-7r-alfa/gama/c, composto, composição farmacêutica, método para tratar uma doença em um paciente e ácido nucleico
CL2019003408A1 (es) Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407)
CL2015001849A1 (es) Anticuerpos anti-lamp1 y conjugados anticuerpos fármaco, y usos de estos
CU23792A3 (es) Novedosos anticuerpos antiproliferación
CL2024000834A1 (es) Proteína mutante de interleucina-2 y fusión de la misma
BR112021008774A2 (pt) Formulação farmacêutica, agente de ligação, métodos para tratamento de uma doença, para produzir uma formulação farmacêutica, para induzir a morte celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, uso de uma formulação farmacêutica
CL2024002653A1 (es) Anticuerpos anti-gd2, inmunoconjugados y usos terapéuticos de los mismos
JP2011507913A5 (es)
AR131398A1 (es) Tratamiento de enfermedades autoinmunitarias
AR125753A1 (es) Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
PE20252244A1 (es) Proteinas de fusion fc de il-12

Legal Events

Date Code Title Description
FA Abandonment or withdrawal